⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
REGN News
Regeneron Pharmaceuticals Inc
Ric Burns' Acclaimed NEW YORK: A DOCUMENTARY FILM Returns with Two New Films September 21st and 22nd On PBS
prnewswire.com
AMX
GOOG
CMCSA
IBM
MSFT
NVDA
INTC
META
AMZN
NFLX
ABNB
UBER
LYFT
TSLA
GM
F
RIVN
NIO
XPEV
LI
PLTR
SNOW
CRM
ADBE
GOOGL
MSCI
SPGI
BKNG
EXPE
MAR
H
WYNN
LVS
MGM
CHTR
VZ
T
QCOM
AMD
MU
AMAT
ASML
TXN
NXPI
ON
ADI
LRCX
KLAC
MRVL
WDC
SE
BABA
JD
PDD
BIDU
BILI
IQ
VIPS
HTHT
NTES
EDU
BEKE
RMAX
Z
HOFT
PG
KO
PEP
MCD
SBUX
YUM
CMG
WEN
CAKE
BJRI
EAT
DRI
BLMN
TH
QSR
SONO
BBY
WMT
TGT
HD
LOW
COST
TJX
ROST
M
KSS
URBN
ANF
AEO
LULU
NKE
UA
CROX
RL
PVH
TPR
CPRI
KHC
GIS
CL
EL
ORCL
SAP
ACN
HPQ
DELL
CSCO
INTU
PYPL
AXP
V
MA
JPM
BAC
WFC
C
MS
GS
SCHW
RJF
LPLA
BEN
IVZ
AB
PGR
ALL
TRV
CB
UNM
MET
PRU
AIG
LNC
GL
CCI
AMT
EQIX
DLR
COR
NTAP
STX
WD
CDNS
SNPS
QTRX
REGN
GILD
AMGN
BMY
ABBV
LLY
PFE
MRK
JNJ
BIIB
VRTX
ALKS
AZN
SNY
NVS
CRSP
EDIT
NTLA
BNTX
MRNA
EXAS
ILMN
ROKU
CRWD
COIN
MARA
RIOT
FTFT
BTBT
CLSK
HUT
GLXY
NNDM
IONQ
RIG
NVCR
CRBU
ACRS
APLS
AXSM
CLDX
CRBP
CUE
CYTK
DASH
GRWG
PLUG
FCEL
BE
NEE
DUK
SO
EXC
SRE
PCG
Levi & Korsinsky Urges Regeneron Pharmaceuticals, Inc. (REGN) Shareholders to Act Before Lead Plaintiff Deadline September 14, 2026
accessnewswire.com
REGN
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
globenewswire.com
REGN
Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) Over Securities Violations - Contact Levi & Korsinsky Today
accessnewswire.com
REGN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
prnewswire.com
EYPT
REGN
REGN Investor Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Notice - Contact SueWallSt
prnewswire.com
REGN
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN
prnewswire.com
REGN
2026 Back of the Eye Disorders Market Research Report (2nd Edition): A Development Pipeline Consisting of ~690 Approved or Clinical-Stage Therapeutic Candidates
globenewswire.com
KODK
OTLK
ALDX
OCUL
REGN
ABBV
NVS
BHC
SUN
Join Class Action to Recover Losses from Regeneron Pharmaceuticals, Inc. (REGN) - Contact Levi & Korsinsky Before September 14, 2026
accessnewswire.com
REGN
REGN Stockholders Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
accessnewswire.com
REGN